Flow cytometric detection of complement-activating HLA antibodies

Cytometry Part B - Clinical Cytometry

Volumn 62, Issue 1, 2004, Pages 39-45

  Schönemann, Constanze ^a   Lachmann, Nils ^a   Kiesewetter, Holger ^a   Salama, Abdulgabar ^a  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

Author keywords

Complement dependent lymphocytotoxicity; Crossmatch; Flow cytometry; HLA antibody; Transplantation

Indexed keywords

CD19 ANTIGEN; CD3 ANTIGEN; HLA ANTIBODY; HLA ANTIGEN CLASS 1; HLA ANTIGEN CLASS 2; PROPIDIUM IODIDE;

ARGON LASER; ARTICLE; B LYMPHOCYTE; CELL DAMAGE; COMPLEMENT DEPENDENT CYTOTOXICITY; CONTROLLED STUDY; FLOW CYTOMETRY; HUMAN; HUMAN CELL; MALE; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN BINDING; SPECTRUM; T LYMPHOCYTE;

COMPLEMENT ACTIVATION; FLOW CYTOMETRY; HISTOCOMPATIBILITY TESTING; HLA ANTIGENS; HUMANS; ISOANTIBODIES; LEUKOCYTES, MONONUCLEAR; REPRODUCIBILITY OF RESULTS; TRANSPLANTATION;

EID: 7744233269     PISSN: 15524949     EISSN: None     Source Type: Journal    
DOI: 10.1002/cyto.b.20027     Document Type: Article

References (39)

1. Rodey GE. HLA beyond tears. Atlanta: De Novo Inc.; 1991.
2. Kissmeyer-Nielsen F, Olsen S, Petersen VP, Fjeldborg O. Hyperacute rejection of kidney allografts associated with pre-existing humoral antibodies against donor cells. Lancet 1966;i:662-665.
3. Patel R, Terasaki PI. Significance of a positive crossmatch test in kidney transplantation. N Engl J Med 1969;280:735-739.
4. Halloran PF, Wadgymar A, Ritchie S, Falk J, Solez K, Srinivasa NS. The significance of the anti-class I antibody response. Transplantation 1990;49:85-91.
5. Sumitran-Karuppan S, Lindholm A, Möller E. Fewer acute rejection episodes and improved outcome in kidney-transplanted patients with selection criteria based on crossmatching. Transplantation 1992;53:666-673.
6. Harmer AW. Utilization of crossmatch techniques for renal transplantation. Curr Opin Nephrol Hypertens 1998;7:687-690.
7. Sumitran S, Clinical importance of HLA-specific and non-HLA-specific antibodies in allogeneic kidney transplantation. Adv Nephrol 2000;30:29-39.
8. Tambur AR, Bray RA, Takemoto SK, Mancini M, Costanzo MR, Kobachigawa JA, D'Amico CL, Kanter KR, Berg A, Vega JD, Smith AL, Roggero AL, Ortegel JW, Wilmoth-Hosey L, Cecka JM, Gebel HM. Flow cytometric detection of HLA-specific antibodies as a predictor of heart allograft rejection. Transplantation 2000;70:1055-1059.
9. Dilioglou S, Cruse JM, Lewis RE. High panel reactive antibody against cross-reactive group antigens as a contraindication to renal allotransplantation. Exp Mol Pathol 2001;71:73-78.
10. Worthington JE, Martin S, Al-Hussein DM, Dyer PA, Jonson RWG. Posttransplantation production of donor HLA-specific antibodies as a predictor of renal transplant outcome. Transplantation 2003;75:1034-1040.
11. Scornik JC. Detection of alloantibodies by flow cytometry: relevance to clinical transplantation. Cytometry 1995;22:259-263.
12. Bittencourt MC, Rebibou JM, Saint-Hillier Y, Chabod J, Dupont I, Chalopin JM, Herve P, Tiberghien P. Impaired renal graft survival after a positive B-cell flow-cytometry crossmatch. Nephrol Dial Transplant 1998;13:2059-64.
13. Lobashevsky AL, Senkbeil RW, Shoaf J, Mink C, Rowe C, Lobashevsky ES, Burke R, Hudson S, Deierhoi MH, Thomas JM. Specificity of preformed alloantibodies causing B cell positive flow crossmatch in renal transplantation. Clin Transplant 2000;14:533-542.
14. Karpinski M, Rush D, Jeffrey J, Exner M, Regele H, Dancea S, Pochino D, Birk P, Nickerson P. Flow cytometric crossmatching in primary renal transplant recipients with a negative anti-human globulin enhanced cytotoxicity crossmatch. J Am Soc Nephrol 2001;12:2807-2814.
15. Crenshaw RL, Magnone M, Scantleburry V, Thacker L. Is a positive B-cell crossmatch always bad? Hum Immunol 2003;64(suppl):34.
16. Ting A. The lymphocytotoxic crossmatch test in clinical renal transplantation. Transplantation 1983;35:403-407.
17. Buelow R, Chiang TR, Monteiro F, Cornejo MC, Ellingson L, Claas F, Gaber O, Gelder F, Kotb M, Orosz C, et al. Soluble HLA antigens and ELISA - a new technology for crossmatch testing. Transplantation 1995;60:1594-1599.
18. Nanni-Costa A, Scolari MP, Ianelli S, Buscaroli A, De Snactis LB, Liviano D'Arcangelo G, Borgnino LC, Buttazzi R, Stefoni S, Bonomini V. Crossmatch testing in renal transplantation: Comparative evaluation between an innovatory ELISA technique and two different standardised CDC methods. Transplant Proc 1997;29:1449-1450.
19. Schönemann C, Groth J, Leverenz S, May G. HLA class I and class II antibodies. Transplantation 1998;65:1519-1523.
20. Sussktad B, Kerman RH, Nelson R, Gregory J, La T, Bayat A, Dang M, Van Buren C, Katz S, Kahan BD. Comparison between enzyme-linked immunosorbent assay and cytotoxic cross-match procedures for detecting IgG anti-donor antibodies. Transplantation 1998;66:1823-1826.
21. Zachary AA, Delaney NL, Lucas DP, Leffell MS. Characterization of HLA class I specific antibodies by ELISA using solubilized antigen targets: I. Evaluation of the GTI QuickID assay and analysis of antibody patterns. Hum Immunol 2001;62:228-235.
22. Garovoy MR, Rheinschmidt MA, Bigos M, Perkins H, Colombe B. Flow cytometry analysis: a high technology crossmatch technique facilitating transplantation. Transplant Proc 1983;15:1939-1944.
23. Scornick JC, Brunson ME, Schaub B, Howard RJ, Pfaff WW. The crossmatch in renal transplantation. Transplantation 1994;57:621-625.
24. Horsburgh T, Martin S, Robson AJ. The application of flow cytometry in histocompatibility testing. Transpl Immunol 2000;8:3-15.
25. Evans PR, Lane AC, Lambert CM, Reynolds WM, Wilson PJ, Harris KR, Slapak M, Lee HA, Smith JL. Lack of correlation between IgG T-lymphocyte flow cytometric crossmatches with primary allograft outcome. Transpl Int 1992;5(suppl)1:609-612.
26. Thistlethwaite JR, Buckingham M, Stuart JK, Gaber AO, Mayes JT, Stuart FP. T cell immunofluorescence flow cytometry cross-match results an cadaver donor renal transplantation. Transplant Proc 1987;19:722-724.
27. Pelletier RP, Orosz CG, Adams PW, Bumgardner GL, Davies EA, Elkhammas E, Henry ML, Ferguson RM. Clinical and economic impact of flow cytometry crossmatching in primary cadaveric kidney and simultaneous pancreas- kidney transplant recipients. Transplantation 1997;63:1639-1644.
28. Harmer AW, Garner S, Bell AE, Anyanwu C, Cavanagh G, Culkin J, Evans PR, Horsburgh T, Martin S, McCloskey D, Reynolds WM, Robson A, Sutton M, Van Dam MG, Shenton BK. Evaluation of the flow cytometric crossmatch. Preliminary results of a multicenter study. Transplantation 1996;61:1108-1111.
29. Shenton BK, Bell AE, Harmer AW, Boyce M, Briggs D, Cavanagh G, Culkin J, Van Dam MG, Evans PR, Haves P, Henderson N, Horsburgh T, Martin S, Preece K, Reynolds W, Robson A, Sutton M, Waters D, Younie M, Garner S. Importance of methodology in flow cytometric crossmatch: a multicenter study. Transplant Proc 1997;29:1454-1455.
30. Terasaki PI, McClelland JD, Park MS, McCurdy B. In: Ray JG, Hare DB, Pedersen PD, Kayhoe DE, editors. Manual of tissue typing techniques. DHW publication NIH 75-545. Bethesda: National Institutes of Health; 1974. p. 67-74.
31. Groth J, Steinmann J, Eckstein V, Müller-Ruchholz W. Freezing of cells - replacement of serum by oxypolygelatine. J Immunol Methods 1991;141:105-109.
32. Mansour I, Messaed C, Azoury M, Klayme S, Naaman R. Panel-reactive antibodies using complement-dependent cytotoxicity, flow cytometry, and ELISA in patients awaiting renal transplantation or transplanted patients: a comparative study. Transplant Proc 2001;33:2844-2847.
33. Wahrmann M, Exner M, Regele KD, Körmöczi GF, Lhotta K, Zlabinger GJ, Böhming GA. Flow cytometry based detection of HLA alloantibody mediated classical complement activation. J Immunol Methods 2003;275:149-160.
34. Terasaki PI. Humoral theory of transplantation. AmJ Transpl 2003;3:665-673.
35. Lillevang ST, Steinbrüchel DA, Kristensen T, Kemp E. A new flowcytometric CDC assay for detection of cytotoxic antibodies applied to hamster-to-rat cardiac transplantation. Transplant Proc 1992;24:537-538.
36. Vermes I, Haanen C, Reutelingsperger C. Flow cytometry of apoptotic cell death. J Immunol Methods 2000;243:167-190.
37. Sumitran-Holgersson S, Wilczek HE, Holgersson J, Söderström K. Identification of the nonclassical HLA molecules, MICA, as targets for humoral immunity associated with irreversible rejection of kidney allografts. Transplantation 2002;74:268-277.
38. Perrey C, Brenchley PE, Johnson RW, Martin S. Association between antibodies specific for endothelial cells and renal transplant failure. Transpl Immunol 1998;6:101-106.
39. Vermehren D, Sumitran-Holgersson S. Isolation of precursor endothelial cells from peripheral blood for donor-specific crossmatching before organ transplantation. Transplantation 2002;74:1479-1486.